At close: December 13 at 3:00:00 PM EST
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
64,270.0000
62,839.0000
52,904.0000
39,986.0000
31,432.0000
Cost of Revenue
35,629.0000
33,452.0000
13,031.0000
9,940.0000
12,237.0000
Gross Profit
28,641.0000
29,387.0000
39,873.0000
30,046.0000
19,195.0000
Operating Expense
384,162.0000
407,888.0000
407,918.0000
231,572.0000
214,377.0000
Operating Income
-355,521.0000
-378,501.0000
-368,045.0000
-201,526.0000
-195,182.0000
Net Non Operating Interest Income Expense
-6,811.0000
-8,574.0000
-10,224.0000
-20,157.0000
-35,048.0000
Other Income Expense
-190,426.0000
-174,672.0000
-84,259.0000
-88,897.0000
-129,346.0000
Pretax Income
-552,758.0000
-561,747.0000
-462,528.0000
-310,580.0000
-359,576.0000
Tax Provision
9,310.0000
-2,416.0000
-33,516.0000
-2,014.0000
-473.0000
Earnings from Equity Interest Net of Tax
-18,735.0000
-18,426.0000
-126.0000
-5,844.0000
-3,909.0000
Net Income Common Stockholders
-547,998.0000
-572,843.0000
-428,325.0000
-298,461.0000
-292,068.0000
Average Dilution Earnings
-12,374.0000
--
--
--
-38,669.0000
Diluted NI Available to Com Stockholders
-547,998.0000
-572,843.0000
-428,325.0000
-298,461.0000
-330,737.0000
Basic EPS
-1.10
-1.37
-1.45
-1.30
-2.20
Diluted EPS
-1.10
-1.37
-1.45
-1.30
-2.35
Basic Average Shares
507,859.0000
419,315.0000
294,774.0000
229,823.0000
132,732.0000
Diluted Average Shares
507,859.0000
419,315.0000
294,774.0000
229,823.0000
140,514.0000
Total Operating Income as Reported
-462,646.0000
-504,315.0000
-401,451.0000
-244,518.0000
-259,393.0000
Total Expenses
419,791.0000
441,340.0000
420,949.0000
241,512.0000
226,614.0000
Net Income from Continuing & Discontinued Operation
-547,998.0000
-572,843.0000
-428,325.0000
-298,461.0000
-292,068.0000
Normalized Income
-399,836.6600
-398,189.4067
-376,926.4447
-210,702.7949
-163,094.8796
Interest Income
--
--
--
24.0000
1,091.0000
Interest Expense
6,811.0000
8,574.0000
10,224.0000
20,157.0000
35,048.0000
Net Interest Income
-6,811.0000
-8,574.0000
-10,224.0000
-20,157.0000
-35,048.0000
EBIT
-545,947.0000
-553,173.0000
-452,304.0000
-290,423.0000
-324,528.0000
EBITDA
-532,020.0000
-539,928.0000
-439,842.0000
-279,416.0000
-313,539.0000
Reconciled Cost of Revenue
26,212.0000
24,532.0000
4,709.0000
2,986.0000
5,189.0000
Reconciled Depreciation
13,927.0000
13,245.0000
12,462.0000
11,007.0000
10,989.0000
Net Income from Continuing Operation Net Minority Interest
-547,998.0000
-572,843.0000
-428,325.0000
-298,461.0000
-292,068.0000
Total Unusual Items Excluding Goodwill
-187,546.0000
-175,408.0000
-55,414.0000
-88,331.0000
-129,143.0000
Total Unusual Items
-187,546.0000
-175,408.0000
-55,414.0000
-88,331.0000
-129,143.0000
Normalized EBITDA
-344,474.0000
-364,520.0000
-384,428.0000
-191,085.0000
-184,396.0000
Tax Rate for Calcs
0.0002
0.0000
0.0001
0.0000
0.0000
Tax Effect of Unusual Items
-39,384.6600
-754.4067
-4,015.4447
-572.7949
-169.8796
12/31/2019 - 9/13/1999
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VXRT Vaxart, Inc.
0.5920
-0.75%
INO Inovio Pharmaceuticals, Inc.
2.3200
-38.30%
IBIO iBio, Inc.
2.3100
-7.97%
CELU Celularity Inc.
2.2200
-3.48%
TNXP Tonix Pharmaceuticals Holding Corp.
0.2405
+5.07%
ENTO Entero Therapeutics, Inc.
0.5839
-5.81%
NVAX Novavax, Inc.
9.11
+1.00%
AUPH Aurinia Pharmaceuticals Inc.
9.37
-3.30%
VIR Vir Biotechnology, Inc.
7.45
+0.27%
JAGX Jaguar Health, Inc.
0.9693
-0.59%